BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1094 related articles for article (PubMed ID: 24284305)

  • 1. Tumor angiogenesis and anti-angiogenic therapies.
    Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
    Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
    Shinkaruk S; Bayle M; Laïn G; Déléris G
    Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The vascular endothelial growth factors and receptors family: Up to now the only target for anti-angiogenesis therapy.
    Tarallo V; De Falco S
    Int J Biochem Cell Biol; 2015 Jul; 64():185-9. PubMed ID: 25936669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model.
    Brave SR; Eberlein C; Shibuya M; Wedge SR; Barry ST
    Angiogenesis; 2010 Dec; 13(4):337-47. PubMed ID: 20953695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
    Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
    Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [VEGF and its receptors as therapeutic target in cancer therapy].
    Gisterek I; Kornafel J
    Przegl Lek; 2006; 63(3):155-7. PubMed ID: 16967703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The VEGF signaling pathway in cancer: the road ahead.
    Stacker SA; Achen MG
    Chin J Cancer; 2013 Jun; 32(6):297-302. PubMed ID: 23419196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.
    Jain RK
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor (VEGF) signaling in tumor progression.
    Roskoski R
    Crit Rev Oncol Hematol; 2007 Jun; 62(3):179-213. PubMed ID: 17324579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Anti-angiogenic drugs].
    Sato Y
    Nihon Rinsho; 2010 Jun; 68(6):1054-8. PubMed ID: 20535955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer.
    Riondino S; Del Monte G; Fratangeli F; Guadagni F; Roselli M; Ferroni P
    Cardiovasc Hematol Agents Med Chem; 2017; 15(1):3-16. PubMed ID: 28137223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy.
    Taylor AP; Osorio L; Craig R; Raleigh JA; Ying Z; Goldenberg DM; Blumenthal RD
    Clin Cancer Res; 2002 Apr; 8(4):1213-22. PubMed ID: 11948135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor angiogenesis and anti-angiogenic therapy.
    Kubota Y
    Keio J Med; 2012; 61(2):47-56. PubMed ID: 22760023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications.
    Ferrara N
    Semin Oncol; 2002 Dec; 29(6 Suppl 16):10-4. PubMed ID: 12516033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Tumor angiogenesis: new approaches to cancer therapy].
    Marmé D
    Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers.
    Rosen LS
    Cancer Control; 2002; 9(2 Suppl):36-44. PubMed ID: 11965229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.
    Tugues S; Koch S; Gualandi L; Li X; Claesson-Welsh L
    Mol Aspects Med; 2011 Apr; 32(2):88-111. PubMed ID: 21565214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.